Sanofi (SAN.PA)


Paris - Paris Delayed Price. Currency in EUR
68.86-0.70 (-1.01%)
At close: 11:35 AM EDT
People also watch:
FP.PABN.PACS.PAOR.PAAI.PA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open69.56
Prev Close69.56
Bid71.12 x 1000
Ask71.74 x 44000
Day's Range68.62 - 69.66
52wk Range24.83 - 93.82
1y Target EstN/A
Market Cap87.57B
P/E Ratio (ttm)21.41
BetaN/A
Volume2,988,266
Avg Vol (3m)12,223
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Kiplinger12 hours ago

    3 Best Dividend Stocks Owned by Warren Buffett

    Berkshire Hathaway has billions invested in Verizon, Sanofi and General Motors.

  • Market Realist13 hours ago

    This Changed Sanofi’s Profitability in 2Q16

    Sanofi reported a net profit of ~1.7 billion euros (about $1.9 billion) in 2Q16—a decline of 8.7% in net profits over 2Q15.

  • American City Business Journals23 hours ago

    The $150 million winner — and the losers — in Pfizer's $14 billion takeout of Medivation

    Dr. David Hung, who guided cancer drug developer Medivation Inc. through a bidding sweepstakes that culminated in a $14 billion cash offer by Pfizer Inc., could reap change-of-control payouts worth upwards of $150 million. Hung, who founded Medivation (MDVN) a dozen years ago, is one of the big winners in the deal that came to light Sunday . A Medivation spokesperson, it should be noted, said the company would not comment about executive compensation or the math behind it.